News

12:11 PMYahoo Finance

Johnson & Johnson (JNJ) Backs new cancer device and leads $100 million depression bet

JNJ+1.1%

10:30 AMYahoo Finance

Johnson & Johnson (JNJ) up 10.4% since last earnings report: Can it continue?

JNJ+1.1%

10:07 AMYahoo Finance

J&J leads Francis Medical investment to fund prostate cancer device

JNJ+1.1%

8:00 AMYahoo Finance

Is there a risk hiding in Johnson & Johnson stock's earnings?

JNJ+1.1%

7:51 AMYahoo Finance

Johnson & Johnson vs. Procter & Gamble: 64 and 70 Straight years of raises. Which dividend King Pays you more over the next decade?

JNJ+1.1%PG+0.3%

6:05 AMYahoo Finance

State Street Health Care SPDR (XLV) adds Eli Lilly and Johnson & Johnson on Nov. 10

LLY−0.5%JNJ+1.1%XLV−0.6%

3:20 PMYahoo Finance

Johnson & Johnson vs. Eli Lilly: Which healthcare giant's stock is a better buy for 2027?

JNJ+1.1%

3:17 PMYahoo Finance

Johnson & Johnson sees a path to Double-Digit growth by 2030. Is the dividend King a buy?

JNJ+1.1%

12:32 PMYahoo Finance

Johnson & Johnson reports Favorable data for bipolar study

JNJ+1.1%

11:36 AMYahoo Finance

Massachusetts Woman’s Family awarded $3.3 million against Johnson & Johnson in Mesothelioma Case

JNJ+1.1%

10:17 AMYahoo Finance

SGOV Yields 3.63%. Can Johnson & Johnson or Verizon Pay retirees more?

JNJ+1.1%

2:11 PMYahoo Finance

Is Johnson & Johnson (JNJ) below fair value on cash Flow?

JNJ+1.1%

10:28 AMYahoo Finance

Johnson & Johnson says Caplyta Improves Manic Symptoms in Second Phase 3 study

JNJ+1.1%

10:17 AMYahoo Finance

$300,000 in Duke Energy, Philip Morris and Johnson & Johnson: Here’s what it Pays

DUK−0.1%JNJ+1.1%

8:00 AMYahoo Finance

Johnson & Johnson announces CAPLYTA (lumateperone) shows significant and rapid improvement in Bipolar Mania in second Pivotal Phase 3 study

JNJ+1.1%

11:19 AMYahoo Finance

What is Johnson & Johnson (JNJ) signaling with two key trial wins?

JNJ+1.1%

10:04 AMYahoo Finance

Johnson & Johnson Showcases Positive trial data for key Autoimmune Therapies

JNJ+1.1%

7:00 AMYahoo Finance

J&J Backs psychedelic-inspired biotech in $100 million round

JNJ+1.1%

6:33 AMYahoo Finance

Johnson & Johnson’s ICOTYDE Meets Primary endpoint in Phase 3 psoriatic arthritis trial

JNJ+1.1%

6:11 AMYahoo Finance

Johnson & Johnson says Icotyde in psoriatic arthritis Disease Meets Primary endpoint in Phase 3 study

JNJ+1.1%

6:03 AMYahoo Finance

ETFs are net sellers of Johnson & Johnson (JNJ) on Nov. 5

JNJ+1.1%

12:34 PMYahoo Finance

Johnson & Johnson (JNJ): Limited analyst upside, but management sees a Clearer Path to growth

JNJ+1.1%

11:00 AMYahoo Finance

Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer

JNJ+1.1%

10:03 AMYahoo Finance

Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients

JNJ+1.1%

10:03 AMYahoo Finance

Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide

JNJ+1.1%